Recent News Releases
Latest CSL News
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group.
Development of the University of Queensland’s vaccine candidate remains CSL’s priority.
The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.
Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.
Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.
Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.
Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia
Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia.
CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.
Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose.
CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B.
Builds on CSL Behring’s promise and commitment to the transplant community.
Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio.
Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
Senior Manager, Communications
Phone: +61 429 609 762